Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

I. Silverberg, Jonathan; Guttman‐Yassky, Emma; Thaçi, Diamant; D. Irvine, Alan; Stein Gold, Linda; Blauvelt, Andrew; L. Simpson, Eric; Chu, Chia‐Yu; Liu, Zhuqing; Gontijo Lima, Renata; Pillai, Sreekumar; Sénéschal, Julien

doi:10.1056/nejmoa2206714

Public

Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis

Published in New England Journal of Medicine • Mar 15, 2023

Authors:

Jonathan I. Silverberg

Emma Guttman‐Yassky

Diamant Thaçi

Abstract

BACKGROUND: Lebrikizumab, a high-affinity IgG4 monoclonal antibody targeting interleukin-13, prevents the formation of the interleukin-4Rα-interleukin-13Rα1 heterodimer receptor signaling complex. METHODS: We conducted two identically designed, 52-week, randomized, double-blind, placebo-controlled, ...

Subject

Atopic dermatitis

Dermatology

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!